Skip to Content
ProceedingsProceedings
  • Abstract
  • Open Access

4 February 2024

Changes in Gut Microbiota and Serum Metabolites in Patients with Extreme Obesity †

,
,
,
,
,
and
1
Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia
2
Department of Biological and Medical Science, Faculty of Physical Education and Sport, Comenius University in Bratislava, 814 69 Bratislava, Slovakia
3
Institute of Hygiene, Faculty of Medicine, Comenius University in Bratislava, 812 72 Bratislava, Slovakia
4
Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 01 Martin, Slovakia

Abstract

Background and Objectives: In recent years, the crucial role of gut microbiota in the development and regulation of obesity and related metabolic conditions has been increasingly explored. This prospective cross-sectional study aimed to examine the differences in gut microbiota composition and energy metabolites between non-diabetic individuals with extreme obesity (EO) and healthy lean controls (HLC). Methods: A total of 19 non-diabetic participants with EO (average age ± SD: 35.4 ± 7.0 years, average BMI ± SD: 48.8 ± 6.7 kg.m−2) and 23 HLC participants (average age ± SD: 31.7 ± 14.8 years, average BMI ± SD: 22.2 ± 1.7 kg.m−2) were investigated. Fecal microbiota was analyzed and classified using specific primers targeting the V1–V3 region of 16S rDNA. Serum metabolites were characterized by nuclear magnetic resonance spectroscopy. Multivariate statistical analysis and Random Forest models were employed to identify predictors with the highest variable importance. Results: A significantly reduced microbial α-diversity; lower relative abundance of beneficial bacterium Akkermansia and SCFA-producing bacteria Eubacterium hallii, Butyrivibrio, Marvinbryantia, and Coprococcus; and increased abundance of pathogenic bacteria Bilophila and Fusobacterium were found in individuals with EO. Interestingly, energy metabolites (citrate and acetate), IR HOMA, and insulin were pinpointed as the most important predictors with exceptional ability to differentiate between EO and HLC participants by the Random Forest machine learning analysis. Conclusion: The findings suggest that changes in gut microbiota and serum acetate and citrate levels in patients with extreme obesity may serve as potential biomarkers for early progression to Type 2 diabetes. Consequently, weight loss interventions and non-invasive manipulation of gut microbiota composition in these patients could offer a novel strategy for managing obesity and related disorders.

Author Contributions

Conceptualization, A.P. and V.B.; methodology, I.H. and J.B.; software, M.G.; validation, E.B., A.P. and V.B.; formal analysis, L.K.; investigation, L.K.; resources, V.B.; data curation A.P., L.K and V.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by Grant No. APVV-17-0099 and APVV-22-0047, as well as VEGA Grant No. VEGA 1/0260/21.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Bratislava Self-Governing Region No.05239/2016/HF; date of approval 28 June 2016).

Data Availability Statement

The data presented in this study are available on request from the corresponding author (accurately indicate status).

Conflicts of Interest

The authors declare no conflicts of interest.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.